Literature DB >> 8198334

Increased incidence of thyroid cancer in patients with primary hyperparathyroidism: a continuing dilemma.

I J Fedorak1, G Salti, N Fulton, C Schark, F H Straus, E L Kaplan.   

Abstract

A number of previous studies have reported a greater incidence of thyroid disease in patients with primary hyperparathyroidism (HPT) than in normal patients. However, few of these studies utilized controls, and most have dealt only with gross thyroid nodules and not with total histologic abnormalities. In order to clarify this problem, thyroid pathology was determined in each of 100 consecutive patients operated upon for HPT. Thyroid nodules were excised, but in addition, a random biopsy of the thyroid was performed in all cases. Patients in this group were matched by age, race, and sex with non-HPT autopsy controls. Histologic slides were reviewed by a single pathologist blinded to the patient's group. Data for the matched pairs were analyzed by the Sign test. There was no significant difference in the prevalence of colloid nodular disease between patients with HPT (45) and the autopsy control group (43, P = 0.2). There was also no significant difference in the prevalence of lymphocytic thyroiditis between HPT patients (24) and control (15, P = 0.07). There was likewise no significant difference in the prevalence of other benign thyroid gland diseases between the two groups. Only nonmedullary cancer of the thyroid was shown to be statistically more prevalent in HPT patients than in autopsy controls (7% vs 0%, respectively; P < 0.02). The major factor that accounts for the coexistence of benign thyroid lesions and HPT is that both are prevalent in middle-aged women.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1994        PMID: 8198334

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  7 in total

1.  Thyroid pathologies accompanying primary hyperparathyroidism: a high rate of papillary thyroid microcarcinoma.

Authors:  Koray Kutlutürk; Emrah Otan; Mehmet Ali Yağcı; Sertaç Usta; Cemalettin Aydın; Bülent Ünal
Journal:  Ulus Cerrahi Derg       Date:  2014-09-01

2.  Coexistence of primary hyperparathyroidism and thyroid disease.

Authors:  M Regal; C Páramo; R Luna Cano; L F Pérez Méndez; J M Sierra; I Rodríguez; R V García-Mayor
Journal:  J Endocrinol Invest       Date:  1999-03       Impact factor: 4.256

3.  Prevalence of thyroid nodules and carcinomas in patients operated on for renal hyperparathyroidism: experience with 339 consecutive patients and review of the literature.

Authors:  Daniel Seehofer; Nada Rayes; Jochen Klupp; Natascha C Nüssler; Frank Ulrich; Klaus-Jürgen Graef; Ralph Schindler; Thomas Steinmüller; Ulrich Frei; Peter Neuhaus
Journal:  World J Surg       Date:  2005-09       Impact factor: 3.352

4.  Concomitant thyroid disease and primary hyperparathyroidism in patients undergoing parathyroidectomy or thyroidectomy.

Authors:  Marie-Christine Wright; Kelly Jensen; Hossam Mohamed; Carolyn Drake; Khuzema Mohsin; Dominique Monlezun; Nuha Alsaleh; Emad Kandil
Journal:  Gland Surg       Date:  2017-08

5.  Benign and Malignant Thyroid Gland Diseases in the Patients with Primary Hyperparathyroidism.

Authors:  Mehmet Celik; Sibel Guldiken; Semra Ayturk; Buket Yilmaz Bulbul; Ebru Tastekin; Nuray Can; Atakan Sezer; Funda Ustun; Ahmet Kucukarda
Journal:  Int J Appl Basic Med Res       Date:  2017 Apr-Jun

6.  Resistance to Thyroid Hormones: A Case-Series Study.

Authors:  Rossella Cannarella; Marco Musmeci; Vincenzo Garofalo; Tiziana A Timpanaro; Guido Leone; Manuela Caruso; Paolo E Maltese; Rosita A Condorelli; Sandro La Vignera; Aldo E Calogero
Journal:  Int J Mol Sci       Date:  2022-09-24       Impact factor: 6.208

7.  Increased incidence of malignancy in patients with primary hyperparathyroidism

Authors:  Melia Karaköse; Muhammet Kocabaş; Mustafa Can; Hatice Çalışkan Burgucu; İlker Çordan; Mustafa Kulaksızoğlu; Feridun Karakurt
Journal:  Turk J Med Sci       Date:  2021-08-30       Impact factor: 0.973

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.